Summary: FDA marketing rules draw a clear line: you sell the benefit, but you don’t rewrite the label. Product names, taglines, and claims all signal “intended use,” and reviewers read between every line. Teams that anchor copy to approved language, build an internal claim grid, and pressure-test campaigns before launch protect both revenue and reputation. In the 80s and 90s, pharmaceutical brand names tried to tell Read More
When Marketing Outruns Approval: What Regulated Industries Can Learn From Pharma
Summary: Pharmaceutical marketing operates at the edge of federal regulation, competitor scrutiny, and scientific proof. Recent Lanham Act disputes, including Section 43(a) claims tied to product labeling and advertising, show how quickly ambition can outpace compliance. The lessons extend far beyond pharma. Any regulated industry making performance or safety claims faces similar exposure when substantiation lags Read More
Contractors and Employees: The Differences and When to Transition
When companies first start up, it’s common, and often efficient, for them to rely on independent contractors. Contractors bring flexibility, lower overhead, and minimal compliance burdens. That works when you’re small. But when contractors end up working exclusively for your company, with you deciding what they do, when they work, and how they operate, you’re risking misclassification, and that opens a legal can of Read More
BAKER JENNER CLIENT ALERT: FinCEN Eliminates Corporate Transparency Act
Reporting Requirements for U.S. Companies and U.S. Persons On March 26, 2025, the Financial Crimes Enforcement Network (FinCEN) issued a new rule that eliminates Corporate Transparency Act (CTA) reporting requirements for U.S. companies and U.S. persons. This marks a significant shift from earlier guidance and deadlines that had many businesses preparing to file. What Changed? U.S. companies and Read More
Why Salary Alone Doesn’t Make an Employee Exempt
Businesses often assume that paying an employee a salary means they don’t have to worry about overtime. That’s a costly mistake. The Fair Labor Standards Act (FLSA) sets strict requirements for classifying employees as exempt from overtime pay, and salary is just one piece of the equation. A recent court decision on the Department of Labor’s (DOL) salary threshold changes has added another layer of confusion, making Read More
BAKER JENNER CLIENT ALERT! FIFTH CIRCUIT COURT DECISION CREATES UNCERTAINTY FOLLOWING CORPORATE TRANSPARENCY ACT REPORTING DEADLINE
The Fifth Circuit Court of Appeals recently issued a ruling that vacates the Corporate Transparency Act (CTA) reporting requirements as implemented by FinCEN. This decision has significant implications for businesses, particularly those located in the Fifth Circuit (Louisiana, Mississippi, and Texas), even though the January 13, 2025, compliance deadline has already passed. For background on the CTA’s reporting Read More
BAKER JENNER CLIENT ALERT! REPORTING DEADLINE REINSTATED AND EXTENDED TO JANUARY 13, 2025 UNDER THE CORPORATE TRANSPARENCY ACT
Following a recent appellate court decision, the reporting requirements under the Corporate Transparency Act (CTA) have been reinstated. The Financial Crimes Enforcement Network (FinCEN) has extended the compliance deadline for entities created before January 1, 2024, to January 13, 2025. For background on the CTA and its original reporting requirements, see our earlier Read More
BAKER JENNER CLIENT ALERT! REPORTING DEADLINE LOOMS UNDER THE CORPORATE TRANSPARENCY ACT
The below is merely informational and does not communicate, whether intentionally or otherwise, any legal, compliance or other advice. As previously shared in our March 2024 article, The Corporate Transparency Act: A New Era For Business Reporting, January 1, 2025 marks a looming deadline for businesses to disclose “beneficial ownership information,” or BOI, to the Financial Crimes Enforcement Network (FinCEN). Read More
The Corporate Transparency Act: A New Era for Business Reporting
The below is merely informational and does not communicate, whether intentionally or otherwise, any legal, compliance or other advice. Ostensibly intended as an anti-money laundering tool, the Corporate Transparency Act (CTA) constitutes a significant intrusion by the federal government into the affairs of domestic and foreign corporate entities otherwise excluded from U.S. public disclosure requirements. Effective Read More
FEDERAL COURT RULES THE FEDERAL CORPORATE TRANSPARENCY ACT IS UNCONSTITUTIONAL
BAKER JENNER CLIENT ALERT! The below is merely informational and does not communicate, whether intentionally or otherwise, any legal, compliance, or other advice. In our blog article, to be released later this month, we discuss the Corporate Transparency Act or “CTA,” which became effective January 1 of this year. The CTA is a sweeping piece of federal anti-money laundering legislation that, if it stands – Read More
